Hesteriosciences Profit & Loss Annual

BSE: 524669 | NSE: HESTERBIO | ISIN: INE782E01017 | Sector: Biotechnology & Drugs

2,642.95 +263.80 (11.09%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	304.55	266.09	235.01	214.33
Total Revenue	304.55	266.09	235.01	214.33
Costof Revenue Total	95.88	95.56	76.40	60.37
Gross Profit	208.67	170.53	158.61	153.96
Selling/ General/ Admin Expenses Total	64.13	116.18	95.90	80.37
Depreciation/ Amortization	17.17	20.70	16.58	13.31
Unusual Expense( Income)	-4.61	-4.41	-0.42	-
Other Operating Expenses Total	90.88	3.74	2.72	4.92
Total Operating Expense	263.46	231.77	191.17	158.98
Operating Income	41.09	34.32	43.83	55.36
Interest Inc( Exp) Net- Non- Op Total	-197.75	-59.68	-11.32	-47.68
Other Net	10.64	11.78	10.68	2.82
Net Income Before Taxes	31.95	40.15	53.50	50.10
Provisionfor Income Taxes	10.79	12.12	14.02	15.41
Net Income After Taxes	21.17	28.04	39.48	34.70
Minority Interest	-2.28	-1.41	-0.16	-0.27
Net Income Before Extra Items	18.89	26.63	39.32	34.43
Net Income	18.89	26.63	39.32	34.43
Income Availableto Com Excl Extra Ord	18.89	26.63	39.32	34.43
Income Availableto Com Incl Extra Ord	18.89	26.63	39.32	34.43
Diluted Net Income	18.89	26.63	39.32	34.43
Diluted Weighted Average Shares	0.76	0.85	0.85	0.85
Diluted EPS Excluding Extra Ord Items	24.88	31.30	46.22	40.47
DPS- Common Stock Primary Issue	6.00	8.00	10.00	10.00
Diluted Normalized EPS	20.86	27.67	45.75	43.16
Gain( Loss)on Saleof Assets	-	0.16	1.25	-33.06